A new trial suggests that pirfenidone, an approved treatment for idiopathic pulmonary fibrosis, may also reduce myocardial fibrosis in patients with heart failure who have a preserved left ventricular ejection fraction.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Scientific Reports Open Access 10 October 2023
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Lewis, G. A. et al. Nat. Med. https://doi.org/10.1038/s41591-021-01452-0 (2021).
Cleland, J. G. F. et al. Eur. Heart J. 42, 2331–2343 (2021).
Pellicori, P. et al. Eur. J. Heart Fail. https://doi.org/10.1002/ejhf.2220 (2021).
Pellicori, P. et al. Eur. J. Heart Fail. 22, 1711–1723 (2020).
Pellicori, P. et al. Cardiovasc. Res. 116, 91–100 (2020).
Cleland, J. G. F. et al. Eur. Heart J. 39, 26–35 (2018).
Cleland, J. G. F. et al. Eur. Heart J. 42, 684–696 (2020).
Gonzalez, A., Schelbert, E. B., Diez, J. & Butler, J. J. Am. Coll. Cardiol. 71, 1696–1706 (2018).
Aimo, A. et al. Pharmacol. Res. 155, 104694 (2020).
Lopez, B. et al. J. Am. Coll. Cardiol. 67, 251–260 (2016).
Lopez, B. et al. Nat. Rev. Cardiol. 18, 479–498 (2021).
Mason, T. et al. JACC Cardiovasc. Imaging 14, 1164–1173 (2021).
J.G.F.C. has received research funding from Torrent Pharmaceuticals, which has an advanced glycation-end-product breaker in development.
About this article
Cite this article
Cleland, J.G.F., Pellicori, P. & González, A. A novel treatment for heart failure targets myocardial fibrosis. Nat Med 27, 1343–1344 (2021). https://doi.org/10.1038/s41591-021-01457-9
This article is cited by
Scientific Reports (2023)